Spero Therapeutics Q1 2024 GAAP EPS $(0.24) Misses $(0.04) Estimate, Sales $9.267M Miss $21.533M Estimate
Portfolio Pulse from Benzinga Newsdesk
Spero Therapeutics (NASDAQ:SPRO) reported Q1 2024 GAAP EPS of $(0.24), missing the $(0.04) estimate by 500%. Sales were $9.267M, missing the $21.533M estimate by 56.96%. Despite the misses, EPS improved by 4% YoY and sales increased by 347.90% YoY.
May 15, 2024 | 8:31 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Spero Therapeutics reported Q1 2024 GAAP EPS of $(0.24), missing the $(0.04) estimate by 500%. Sales were $9.267M, missing the $21.533M estimate by 56.96%. Despite the misses, EPS improved by 4% YoY and sales increased by 347.90% YoY.
The significant misses on both EPS and sales estimates are likely to negatively impact SPRO's stock price in the short term. However, the YoY improvements in EPS and sales may provide some support.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100